Post A Reply
Allstocks.com's Bulletin Board
Micro Penny Stocks, Penny Stocks $0.10 & Under
IGNT .... news & volume
» Post A Reply
Post A Reply
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by Bought the bridge: [QB] Anyone see this yesterday? Jump today? It came out at 3:15 p.m. yesterday - I didn't see it though. Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company is ahead of schedule with the debt reduction program, and with export product expansion and distribution. The company implemented a debt reduction program in March-2009 with efforts focused on operational debts accrued during 2008. To date, the company has paid down all operational debts that were accrued in 2008. "These were debts that we expected to pay off by the end of August-2009; however, we have tightened our belts and paid them off 60 days early," stated Thomas J. Neavitt, Chief Financial Officer. In addition, the company has heavily invested in the marketing and advertising of the new Oxyview Nasal Cannula, using effective publication sources such as COPD Digest and MedCo Forum. Further, the company is also ahead of schedule with their ISO Certification for export marketing and distribution of their Oxyview product line. Since the introduction of the new Oxyview Nasal Cannula "All-In-One" last week, the company has received hundreds of new distributor inquiries and is now evaluating all of the new distributors. "Ingen is receiving 10-20 new distributor inquiries daily, and this is a difficult process involving due diligence. We want distributors that have been in business for at least 5 years, and have a solid home oxygen patient market in their territory," stated Christopher Wirth, Chief Operations Officer. "We are all very pleased with the direction this company has taken: reducing our debt, increasing sales and distribution worldwide, and our commitment to our shareholders and their investment. All of these activities play a role in the success and future of this company. We expect to stay ahead of schedule and prosper in the very near future," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board. About Oxyview: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S. and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters. The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472 [URL=http://www.ingen-tech.com]www.ingen-tech.com[/URL] Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission. This news release was distributed by GlobeNewswire, [URL=http://www.globenewswire.com]www.globenewswire.com[/URL] SOURCE: Ingen Technologies, Inc. Ingen Technologies, Inc. Chris Wirth 909-790-7180 info*ingen-tech.com [URL=http://www.ingen-tech.com]www.ingen-tech.com[/URL] [/QB][/QUOTE]
Instant UBB Code™
What is UBB Code™?
Disable Graemlins in this post.
*** Click here to review this topic. ***
Allstocks.com Message Board Home
© 1997 - 2019 Allstocks.com. All rights reserved.